A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics
2016
Journal of Cardiovascular Pharmacology
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide requiring therapy. Despite recent advances in catheter-based and surgical therapy, antiarrhythmic drugs (AAD) remain the mainstay of treatment for symptomatic AF. However, response in individual patients is highly variable with over half the patients treated with rhythm control therapy experiencing recurrence of AF within a year. Contemporary AADs used to suppress AF are incompletely and unpredictably effective
doi:10.1097/fjc.0000000000000280
pmid:25970841
pmcid:PMC4639470
fatcat:mmevurq5yrgjtm7u2h6iagc5fa